3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
47
Neoplasms
5
Neoplasm Metastasis
5
Metastatic Castration-Resistant Prostate Cancer
3
Adenocarcinoma
3
Recurrence
2
Prostatic Neoplasms, Castration-Resistant
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Bulbo-Spinal Atrophy, X-Linked
2
mCRPC
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer Metastatic
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasm, Residual
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Lymphoma, Follicular
1
Fatigue
1
Depression
1
Colorectal Neoplasms
1
Castration Resistant Metastatic Prostate Cancer
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Interventions
Cisplatin
6
Platinum
5
Pemetrexed
5
1,2-diaminocyclohexaneplatinum II citrate
5
pembrolizumab
4
atezolizumab
2
Radiotherapy
2
Radiation
2
Nivolumab
2
Ipilimumab
2
Gemcitabine
2
Cyclophosphamide
2
Carboplatin
2
tremelimumab
1
methoxyamine
1
fludarabine
1
decitabine and cedazuridine drug combination
1
cediranib
1
anetumab ravtansine
1
aldesleukin
1
Trioxsalen
1
Tissue Banks
1
Radiotherapy, Intensity-Modulated
1
Proton Therapy
1
Phototherapy
1
Photochemotherapy
1
Pharmacogenomic Testing
1
Pharmaceutical Preparations
1
Interleukin-2
1
Influenza Vaccines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
enzalutamide
×
90 days
×
Clear all
No trials found.